Alternatives to apixaban
2 same-class SPL records vs apixaban - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Eliquis
How to read a high-report FAERS peer set
apixaban ranks in the upper FAERS-volume third of the corpus (#118 of 524); 2 same-class peers are listed for field comparison only. Labeled indication field for apixaban: Apixaban is used to lower the chance of stroke in people with an irregular heartbeat called atrial fibrillation.
Top FAERS reaction fields for apixaban total 27,042 reports across 10 reactions, set beside edoxaban, rivaroxaban. Counts are exposure-weighted submissions, not per-patient risk.
About apixaban
Apixaban (Eliquis) is a medicine that helps prevent blood clots. It is used to lower the risk of stroke and other serious problems caused by blood clots.
Used for: Apixaban is used to lower the chance of stroke in people with an irregular heartbeat called atrial fibrillation. It also prevents blood clots in the legs (deep vein thrombosis or DVT) that can happen after hip or knee replacement surgery. Apixaban is also used to treat DVT and lung clots (pulmonary embolism or PE), and to prevent them from coming back.
2 Direct Oral Anticoagulant (Factor Xa Inhibitor) peers (wide set)
edoxaban
RxSavaysa
Savaysa is used to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, a type of irregular heartbeat. It is also used to treat blood clots in the deep veins of your legs (DVT) or in your lungs (PE). You will likely need to take another medicine to prevent blood clots for 5 to 10 days before starting Savaysa for DVT or PE.
rivaroxaban
RxXarelto
This medicine can help prevent strokes in people with an irregular heartbeat called atrial fibrillation. It also treats blood clots in the legs (deep vein thrombosis or DVT) and lungs (pulmonary embolism or PE). Rivaroxaban can also lower the risk of these clots coming back. It is also used to prevent blood clots after hip or knee replacement surgery and in acutely ill patients.
apixaban vs edoxaban & rivaroxaban · FAERS reaction fields
FAERS top-reaction field "Atrial Fibrillation" shows the widest count spread between apixaban and edoxaban, rivaroxaban in this extract (3,970-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | apixaban | edoxaban | rivaroxaban |
|---|---|---|---|
| Atrial Fibrillation | 3,970 | - | - |
| Dyspnoea | 3,598 | - | 7,149 |
| Cerebrovascular Accident | 3,508 | - | 5,543 |
| Thrombosis | 2,806 | - | 4,915 |
| Cardiac Disorder | 2,509 | - | - |
| Death | 2,332 | - | 6,030 |
| Fall | 2,287 | - | 6,003 |
| Fatigue | 2,193 | - | 6,546 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
apixaban FAERS volume vs class peers
FAERS volume band
apixaban is FAERS corpus rank #118 of 524 (high volume tercile). Top-reaction field total: 27,042.
Frequently Asked Questions
Where does apixaban sit in FAERS report volume vs Direct Oral Anticoagulant (Factor Xa Inhibitor) peers? ▼
Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for apixaban: see also the generic vs brand label guide when reading Eliquis SPL strings.
Read our methodology - how this data is sourced, computed, and verified.